论文部分内容阅读
目的评价多西紫杉醇、卡培他滨和顺铂(TXP)联合化疗方案对转移性鼻咽癌的疗效及其毒性。方法我们对22名转移性鼻咽癌进行了回顾性研究。所有患者接受21d为一周期的方案:第1天静脉滴注多西紫杉醇60mg/m2、第1~14天口服卡培他滨1250mg/m2,第1~3天静脉滴注顺铂20mg/m2。结果在这些患者中,14(63%)例获得部分缓解,2(9%)例获得完全缓解,5(23%)病情稳定。该组患者中总有效率为72%,1年生存率为68%,无进展生存期和总生存期分别为8个月和14个月。主要毒付作用为骨髓抑制,7(32%)例患者经历3/4级粒细胞缺乏症,5(23%)例患者出现3/4级贫血;其他毒付反应均可耐受或可逆。结论 TXP方案是一个安全和有效的转移性鼻咽癌治疗方案,本研究结果与近期文献结果有可比性。
Objective To evaluate the efficacy and toxicity of docetaxel, capecitabine and cisplatin (TXP) in combination with chemotherapy on metastatic nasopharyngeal carcinoma. Methods We conducted a retrospective study of 22 metastatic nasopharyngeal cancers. All patients underwent a one-cycle regimen for 21 days: docetaxel 60 mg / m 2 on day 1, capecitabine 1250 mg / m 2 on day 1 to day 14, and cisplatin 20 mg / m 2 on days 1 to 3 . Results Of these patients, 14 (63%) achieved partial remission, 2 (9%) achieved complete remission and 5 (23%) had stable disease. The total effective rate was 72%, the 1-year survival rate was 68%, progression-free survival and overall survival were 8 months and 14 months respectively. The primary drug was myelosuppression, with grade 3/4 granulocytosis in 7 (32%) patients and grade 3/4 anemia in 5 (23%) patients; all other drug reactions were tolerated or reversible. Conclusion The TXP regimen is a safe and effective treatment for metastatic nasopharyngeal carcinoma. The results of this study are comparable with those of recent literature.